Avant Diagnostics, Inc. (AVDX) Blazing Trail to Fu
Post# of 104
Posted On: 10/29/2015 5:37:59 PM
Avant Diagnostics, Inc. (AVDX) Blazing Trail to Fulfill Need for Effective Ovarian Cancer Screening Technology
Each year, approximately 20,000 women in the United States get ovarian cancer, which causes more deaths than any other gynecologic cancer, according to the Centers for Disease Control. While the disease often causes signs and symptoms, the signs can be hard to recognize; and for the time being, the market is lacking an available, effective screening test for ovarian cancer. Thanks to one particular advancing technology, however, this could soon change.
Because ovarian cancer symptoms can be hard to recognize, effective screening is vital, and medical diagnostic technology company Avant Diagnostics stands at the edge of breakthrough. The company is currently testing OvaDx®, its sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer faster than ever before.
Research studies with OvaDx indicate high sensitivity and specificity for all types and stages of ovarian cancer. Upon FDA approval, Avant Diagnostics will offer OvaDx as an elective test for women seeking greater wellness and for women in the elevated risk category (which includes something as simple as getting older) for ovarian cancer.
OvaDx works by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. The goal is for OvaDx to be used by doctors for early detection, improved surgical options, more effective chemotherapies, and to supplement existing tests such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant Diagnostics’ technology will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.
That said, it’s worth taking a look at Avant Diagnostics’ progress in bringing this game-changing product to market. The company continues to steadily progress toward FDA 510(k) clearance for OvaDx. DOCRO, Avant Diagnostics’ independent clinical research organization, recently received notification that the previously purchased specimens have been approved and are available for use in the upcoming validation study which will be used to support a pre-submission package to the FDA prior to the commencement of the OvaDx® 510(k) trial.
Continuing on its path toward FDA approval of its groundbreaking diagnostic technology, Avant Diagnostics is poised to promote considerable growth in the ovarian cancer market and deliver a promising solution to a significant unmet medical need.
For more information, visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Each year, approximately 20,000 women in the United States get ovarian cancer, which causes more deaths than any other gynecologic cancer, according to the Centers for Disease Control. While the disease often causes signs and symptoms, the signs can be hard to recognize; and for the time being, the market is lacking an available, effective screening test for ovarian cancer. Thanks to one particular advancing technology, however, this could soon change.
Because ovarian cancer symptoms can be hard to recognize, effective screening is vital, and medical diagnostic technology company Avant Diagnostics stands at the edge of breakthrough. The company is currently testing OvaDx®, its sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer faster than ever before.
Research studies with OvaDx indicate high sensitivity and specificity for all types and stages of ovarian cancer. Upon FDA approval, Avant Diagnostics will offer OvaDx as an elective test for women seeking greater wellness and for women in the elevated risk category (which includes something as simple as getting older) for ovarian cancer.
OvaDx works by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. The goal is for OvaDx to be used by doctors for early detection, improved surgical options, more effective chemotherapies, and to supplement existing tests such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant Diagnostics’ technology will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.
That said, it’s worth taking a look at Avant Diagnostics’ progress in bringing this game-changing product to market. The company continues to steadily progress toward FDA 510(k) clearance for OvaDx. DOCRO, Avant Diagnostics’ independent clinical research organization, recently received notification that the previously purchased specimens have been approved and are available for use in the upcoming validation study which will be used to support a pre-submission package to the FDA prior to the commencement of the OvaDx® 510(k) trial.
Continuing on its path toward FDA approval of its groundbreaking diagnostic technology, Avant Diagnostics is poised to promote considerable growth in the ovarian cancer market and deliver a promising solution to a significant unmet medical need.
For more information, visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)